Corvus Pharmaceuticals (NASDAQ:CRVS) Given Overweight Rating at Cantor Fitzgerald

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research note issued to investors on Thursday, Benzinga reports. They currently have a $4.00 price objective on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 148.45% from the company’s previous close. […]

Related Keywords

,Virtu Financial ,Cantor Fitzgerald ,Nasdaq ,Corvus Pharmaceuticals Company Profile ,Corvus Pharmaceuticals Trading Down ,Institutional Trading Of Corvus Pharmaceuticals ,Renaissance Technologies ,News Ratings For Corvus Pharmaceuticals Daily ,Corvus Pharmaceuticals ,Corvus Pharmaceuticals Inc ,Charles Schwab Investment Management Inc ,Tower Research Capital ,Get Free Report ,Pharmaceuticals Trading Down ,Research Capital ,Street Corp ,Charles Schwab Investment Management ,Corvus Pharmaceuticals Daily ,Nasdaq Crvs ,Ccrvs ,Medical ,Reiterated Rating ,